Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTnm-38, an Novel Epigenetic Immune Activator, at the 2025 ASCO Annual Meeting
TAIPEI, May 22, 2025 /PRNewswire/ — GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-38, an novel epigenetic immune activator for... Read more.
MindHYVE.ai™ and Islamabad Diagnostic Centre Forge Strategic Alliance to Launch AGI-Powered Diagnostic Intelligence Across Pakistan
ISLAMABAD, May 22, 2025 /PRNewswire/ — In a groundbreaking move to elevate clinical diagnostics nationwide, MindHYVE.ai™, a U.S.-based pioneer in orchestrated... Read more.
Rakuten Medical Announces Trial in Progress Poster Presentation at ASCO 2025 and Enrollment Expansion to Taiwan for Global Phase 3 ASP-1929-381
Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025 Global patient enrollment continues, with Taiwan now actively enrolling... Read more.
Jack Henry CEO Greg Adelson to Present at Strategic Decisions Conference
MONETT, Mo., May 22, 2025 /PRNewswire/ — Jack Henry & Associates, Inc.® (Nasdaq: JKHY) announced today that it will be participating in the following... Read more.
Home Manufacturer BOXABL Adopts Bitcoin Treasury Reserve Strategy
LAS VEGAS, May 22, 2025 /PRNewswire/ — BOXABL has adopted a Bitcoin treasury reserve strategy, allowing for a percentage of its assets to acquire Bitcoin.... Read more.
Pivot Bio Announces AgTech Corridor Relocation
Company to Relocate Berkeley Headquarters and Operations to Accelerate the Future of Agtech in the Midwest BERKELEY, Calif., May 22, 2025 /PRNewswire/ — Pivot... Read more.
Johnson & Johnson’s IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia Gravis Market | DelveInsight
The FDA has approved Johnson & Johnson’s anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under... Read more.
ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight
Approximately a year after the FDA rejected its previous approval submission, Abeona announced that the agency had approved ZEVASKYN, its autologous cell-based gene... Read more.
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib)... Read more.
Haivision to Announce Second Quarter Fiscal 2025 Financial Results on June 11, 2025
MONTREAL, May 22, 2025 /PRNewswire/ – Haivision Systems Inc. (“Haivision“) (TSX: HAI), a leading global provider of mission critical, real-time... Read more.